Avelo is focused on addressing the critical need for effective respiratory infection diagnostics, particularly pneumonia, which accounts for a significant number of primary care consultations and deaths globally. Their primary innovation, AveloCollect, is a breath aerosol collector designed to work seamlessly with existing molecular tests. This technology allows for the rapid detection of multiple respiratory tract infections, facilitating timely and appropriate treatment. The process is straightforward, requiring only a two-minute breath collection, followed by sample transfer to a standard lab tube for testing. This ease of use makes AveloCollect suitable for various healthcare settings, enhancing the potential for early diagnosis and intervention.

The impact of Avelo's technology extends beyond individual patient care; it aims to reduce healthcare costs significantly by minimizing hospital admissions and streamlining the diagnostic process. By enabling better diagnosis and tailored treatment options, AveloCollect contributes to the fight against antimicrobial resistance (AMR) by distinguishing between viral and bacterial infections, thereby reducing unnecessary antibiotic prescriptions. This innovative approach not only saves lives but also establishes breath bioaerosols as a novel sample type for standard clinical diagnosis, marking a transformative step in respiratory health management.

Switzerland

Our mission is to save lives by bringing fast and actionable infectious disease diagnosis closer to the patient. Avelo's solution is a breath collection device. It works with existing molecular tests to detect multiple respiratory tract infections causing pneumonia

Avelo

Company Details